Palmitoylethanolamide (PEA) is an endogenous fatty acid amide belonging to the N-acylethanolamine (NAE) class of signaling molecules. It plays a role in a variety of biological functions, including anti-inflammatory, analgesic and neuroprotective. PEA exerts its pharmacological effects by activating peroxisome proliferator-activated receptor alpha (PPAR-α) and possibly indirectly activating the cannabinoid receptor system.
Regarding the clinical study of PEA, several studies have shown that it has a significant relief effect on chronic pain. For example, in a study of lower back pain or sciatic nerve pain, either 600 mg or 300 mg of PEA per day showed greater efficacy than placebo, with higher doses (600 mg) having a more significant effect. In addition, another multicentre randomized controlled trial also showed that PEA was effective in reducing chronic pain caused by different pathological conditions, and its effects were independent of the patient's age or gender.
In addition to pain management, PEA is also being studied for the treatment of depression and other psychiatric disorders. A randomized, double-blind controlled trial found that PEA, as an adjuvant antidepressant therapy, significantly improved patients' Hamilton Depression Scale (HAM-D) scores without significant side effects. These studies support the promise of PEA as a potential anti-inflammatory and neuroprotective agent in a variety of health problems.
Palmitoylethanolamide (PEA) has attracted attention due to its broad bioactivity and potential for clinical applications. Although the current study results indicate significant efficacy, more high-quality studies are needed to further validate its efficacy and safety.